Document Detail


Ranibizumab for Edema of the Macula in Diabetes Study: 3-Year Outcomes and the Need for Prolonged Frequent Treatment.
MedLine Citation:
PMID:  23044909     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE To assess the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. DESIGN Prospective, interventional, multicenter follow-up of a randomized clinical trial. METHODS Patients who agreed to participate between months 24 and 36 (ranibizumab, 28 patients; laser, 22; and ranibizumab + laser, 24) returned monthly and received ranibizumab, 0.5 mg, if foveal thickness (FTH, center subfield thickness) was 250 μm or greater. Main outcome measures were improvement in best-corrected visual acuity (BCVA) and reduction in FTH between months 24 and 36. RESULTS Mean improvement from the baseline BCVA in the ranibizumab group was 10.3 letters at month 36 vs 7.2 letters at month 24 (ΔBCVA letters = 3.1, P = .009), and FTH at month 36 was 282 μm vs 352 μm at month 24 (ΔFTH = 70 μm, P = .006). Changes in BCVA and FTH in the laser group (-1.6 letters and -36 μm, respectively) and the ranibizumab + laser group (+2.0 letters and -24 μm) were not statistically significant. The mean number of ranibizumab injections was significantly greater in the ranibizumab group compared with the laser group (5.4 vs 2.3 injections, P = .008) but not compared with the ranibizumab + laser group (3.3, P = .11). CONCLUSIONS More aggressive treatment with ranibizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab group. More extensive focal/grid laser therapy in the other 2 groups may have reduced the need for more frequent ranibizumab injections to control edema. APPLICATION TO CLINICAL PRACTICE Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00407381.
Authors:
Diana V Do; Quan D Nguyen; Afsheen A Khwaja; Roomasa Channa; Yasir J Sepah; Raafay Sophie; Gulnar Hafiz; Peter A Campochiaro;
Related Documents :
11107689 - Patients' perceived outcomes after stapedectomy for otosclerosis.
22998609 - Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study.
24556959 - The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of ...
24398339 - Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe...
2232769 - Performance of cochlear implant patients as a function of time.
23336859 - Treatment of symptomatic isolated dissection of superior mesenteric artery.
22691669 - Postoperative incentive spirometry use.
21707269 - Haemorrhagic shearing lesions associated with diffuse axonal injury: application of t2 ...
11107689 - Patients' perceived outcomes after stapedectomy for otosclerosis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  Archives of ophthalmology     Volume:  -     ISSN:  1538-3601     ISO Abbreviation:  Arch. Ophthalmol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706534     Medline TA:  Arch Ophthalmol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-7     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differing effects of PTH 1-34, PTH 1-84 and zoledronic acid on bone microarchitecture and estimated ...
Next Document:  Modified Surgical Approach to Cervical Neuromas with Intraforaminal Components: Minimal Invasive Fac...